- Home
- PSNL vs HROW Comparison
PSNL vs HROW Comparison
Compare PSNL & HROW Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | PSNL | HROW |
|---|---|---|
| Founded | 2011 | 1998 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical Specialities | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.7B | 1.7B |
| IPO Year | 2019 | 2008 |
Fundamental Metrics
Financial Performance| Metric | PSNL | HROW |
|---|---|---|
| Price | $15.65 | $27.23 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 5 | 9 |
| Target Price | $15.17 | ★ $65.00 |
| AVG Volume (30 Days) | ★ 2.1M | 623.3K |
| Earning Date | 11-03-2026 | 11-09-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 33.58 | ★ 71.43 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $69,648,000.00 | N/A |
| Revenue This Year | $21.10 | $28.59 |
| Revenue Next Year | $30.66 | $53.17 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $4.96 | $26.96 |
| 52 Week High | $18.89 | $54.98 |
Technical Indicators
Market Signals| Indicator | PSNL | HROW |
|---|---|---|
| Relative Strength Index (RSI) | 40.41 | 28.20 |
| Support Level | $13.68 | N/A |
| Resistance Level | $16.58 | $35.87 |
| Average True Range (ATR) | 0.35 | 1.32 |
| MACD | -0.09 | -0.08 |
| Stochastic Oscillator | 10.70 | 12.76 |
Price Performance
Historical ComparisonAbout PSNL Personalis Inc.
Personalis Inc is a provider of genomic sequencing and analytics solutions to support the development of personalized cancer vaccines and other next-generation cancer immunotherapies. It has one segment, the sale of sequencing and data analysis services. The company' products include ImmunoID NeXT, NeXT Personal, NeXT Dx Test, and other pharma research solutions.
About HROW Harrow Inc.
Harrow Inc is an eyecare pharmaceutical company engaged in the discovery, development, and commercialization of ophthalmic pharmaceutical products for the U.S. market. The company partners with U.S. eyecare professionals to develop products used to manage ophthalmic conditions affecting both the front and back of the eye, such as dry eye disease, cataracts, refractive errors, glaucoma, etc. Its portfolio of branded ophthalmic pharmaceuticals includes Iheezo, Vevye, Byooviz Opuviz, Natacyn, Maxitrol, Maxidex, etc. Additionally, the company's development pipeline comprises candidates like MELT-300, H-N08, CR-01, and MELT-210, being developed to address unmet needs in eye care and selected adjacent markets. Its reportable segments are: Branded, which derives maximum revenue, and ImprimisRx.